Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid
- 21 January 2010
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 69 (2) , 167-178
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Probenecid inhibits the active transport of both anionic and cationic drug molecules at various sites in the body.• Probenecid has been reported to decrease the elimination of several quinolones.• We are not aware of any reports where a mechanism‐based model for the interaction of quinolones and probenecid in humans or animals has been developed.WHAT THIS STUDY ADDS• Pharmacokinetic modelling indicates competitive inhibition of the renal tubular secretion of ciprofloxacin and its metabolite M1 by probenecid.• The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 compared with probenecid, based on molar concentrations.• Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.AIMS: Probenecid influences transport processes of drugs at several sites in the body and decreases elimination of several quinolones. We sought to explore extent, time course, and mechanism of the interaction between ciprofloxacin and probenecid at renal and nonrenal sites.METHODS: A randomized, two‐way crossover study was conducted in 12 healthy volunteers (in part previously published Clin Pharmacol Ther 1995; 58: 532–41). Subjects received 200 mg ciprofloxacin as 30‐min intravenous infusion without and with 3 g probenecid divided into five oral doses. Drug concentrations were analysed by liquid chromatography–tandem mass spectrometry and high‐performance liquid chromatography. Ciprofloxacin and its 2‐aminoethylamino‐metabolite (M1) in plasma and urine with and without probenecid were modelled simultaneously with WinNonlin®.RESULTS: Data are ratio of geometric means (90% confidence intervals). Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h−1[65% reduction (59, 71),P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h−1(66% reduction (57, 73),P < 0.01] for M1 (estimated by modelling). Probenecid reduced ciprofloxacin nonrenal clearance by 8% (1, 14) (P < 0.08). Pharmacokinetic modelling indicated competitive inhibition of the renal tubular secretion of ciprofloxacin and M1 by probenecid. The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 than for probenecid, based on the molar ratio. Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.CONCLUSIONS: Probenecid inhibited the renal tubular secretion of ciprofloxacin and M1, probably by a competitive mechanism and due to reaching >100‐fold higher plasma concentrations. Formation of M1, nonrenal clearance and distribution of ciprofloxacin were not affected.Keywords
This publication has 30 references indexed in Scilit:
- Organic Anion Transporter 3 (Oat3/Slc22a8) Interacts with Carboxyfluoroquinolones, and Deletion Increases Systemic Exposure to CiprofloxacinMolecular Pharmacology, 2008
- The human organic anion transporter 3 (OAT3;SLC22A8): genetic variation and functional genomicsAmerican Journal of Physiology-Renal Physiology, 2006
- A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Transport of organic anions across the basolateral membrane of proximal tubule cells2003
- Mechanisms and clinical implications of renal drug excretion*Drug Metabolism Reviews, 2001
- Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liverHepatology, 1997
- The Clinical Pharmacokinetics of LevofloxacinClinical Pharmacokinetics, 1997
- Clinical Pharmacokinetics of SparfloxacinClinical Pharmacokinetics, 1993
- Capacity-limited renal glucuronidation of probenecid by humansInternational Journal of Clinical Pharmacy, 1992
- Influence of probenecid and paracetamol (acetaminophen) on zidovudine glucuronidation in human liver in vitroBiopharmaceutics & Drug Disposition, 1992